News
Soleno Therapeutics CEO responds to a 415-page short-seller report alleging safety issues tied to the company's newly approved therapy.
The FDA's controversial rejection of a skin cancer therapy from Replimune Group has prompted Krystal Biotech to shut down of a clinical trial involving a similar drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback